Actinium Pharmaceuticals Stock Fundamentals
| ATNM Stock | USD 1.44 0.03 2.13% |
Actinium Pharmaceuticals fundamentals help investors to digest information that contributes to Actinium Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Actinium Stock. The fundamental analysis module provides a way to measure Actinium Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Actinium Pharmaceuticals stock.
At this time, Actinium Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 28th of November 2024, Research Development is likely to grow to about 40.6 M, though EBIT is likely to grow to (49.3 M). Actinium | Select Account or Indicator |
Actinium Pharmaceuticals Company Shares Outstanding Analysis
Actinium Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Actinium Pharmaceuticals Shares Outstanding | 31.2 M |
Most of Actinium Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Actinium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Actinium Shares Outstanding Historical Pattern
Today, most investors in Actinium Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Actinium Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Actinium Pharmaceuticals shares outstanding as a starting point in their analysis.
Actinium Pharmaceuticals Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Actinium Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Actinium Pharmaceuticals has 31.2 M of shares currently outstending. This is 82.72% lower than that of the Biotechnology sector and 70.81% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 94.54% higher than that of the company.
Actinium Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Actinium Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Actinium Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Actinium Pharmaceuticals competition to find correlations between indicators driving Actinium Pharmaceuticals's intrinsic value. More Info.Actinium Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Actinium Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Actinium Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Actinium Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actinium Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actinium Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Actinium Pharmaceuticals by comparing valuation metrics of similar companies.Actinium Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Actinium Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Actinium Pharmaceuticals from analyzing Actinium Pharmaceuticals' financial statements. These drivers represent accounts that assess Actinium Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Actinium Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 32.5M | 94.6M | 123.6M | 257.1M | 135.1M | 86.5M | |
| Enterprise Value | 24.7M | 31.8M | 46.1M | 150.8M | 60.6M | 77.2M |
Actinium Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (576.65) % | ||||
| Current Valuation | (31.71 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 30.10 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 543.04 X | ||||
| Revenue | 81 K | ||||
| Gross Profit | 1.03 M | ||||
| EBITDA | (51.13 M) | ||||
| Net Income | (48.82 M) | ||||
| Cash And Equivalents | 116.33 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 2.11 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 18.83 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (47.34 M) | ||||
| Short Ratio | 5.72 X | ||||
| Earnings Per Share | (1.39) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 49 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 43.99 M | ||||
| Total Asset | 81.44 M | ||||
| Retained Earnings | (337.58 M) | ||||
| Working Capital | 69.77 M | ||||
| Current Asset | 26.48 M | ||||
| Current Liabilities | 4.61 M | ||||
| Net Asset | 81.44 M |
About Actinium Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actinium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actinium Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actinium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 40.2 M | 42.3 M | |
| Cost Of Revenue | 790 K | 829.5 K | |
| Total Revenue | 81 K | 77 K | |
| Stock Based Compensation To Revenue | 47.43 | 49.80 | |
| Sales General And Administrative To Revenue | 164.58 | 172.81 | |
| Research And Ddevelopement To Revenue | 477.41 | 501.28 | |
| Capex To Revenue | 1.89 | 1.98 | |
| Ebit Per Revenue | (640.99) | (608.94) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Actinium Pharmaceuticals Piotroski F Score and Actinium Pharmaceuticals Altman Z Score analysis. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.